Every Form 4 that TherapeuticsMD, Inc. (TXMD) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TXMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TXMD filings page.
TherapeuticsMD (TXMD) reported insider equity activity. Director Tommy G. Thompson received 8,500 restricted stock units (RSUs) on November 3, 2025.
Each RSU represents the right to receive one share of common stock and will vest on November 3, 2028. Following the grant, 8,500 derivative securities were beneficially owned on a direct basis.
TherapeuticsMD (TXMD) director Gail K. Naughton reported the acquisition of 8,500 restricted stock units (RSUs) on November 3, 2025, according to a Form 4 filing. Each RSU represents a right to receive one share of common stock. The RSUs carry a stated price of $0 and are scheduled to vest on November 3, 2028.
Following the transaction, 8,500 derivative securities are shown as beneficially owned in direct form. This reflects a standard equity award to a board member and does not involve an immediate cash transaction.
TherapeuticsMD (TXMD) — Form 4 filing: Director Cooper C. Collins reported an award of 8,500 restricted stock units on November 3, 2025. Each RSU represents the right to receive one share of common stock and carries a price of $0.
The RSUs will vest on November 3, 2028. Following this grant, 8,500 derivative securities are reported as beneficially owned, held directly.
TherapeuticsMD (TXMD) reported an insider equity award: Chief Executive Officer Marlan D. Walker filed a Form 4 disclosing the acquisition of 67,492 non-qualified stock options on 11/03/2025.
The options carry an exercise price of $1.15 per share, are exercisable on 11/03/2025, and expire on 11/03/2035. Each option is exercisable for one share of common stock, for a total of 67,492 underlying shares. The filing lists a derivative price of $0, indicating no cash paid for the grant itself.
Following the reported transaction, Walker beneficially owned 67,492 derivative securities, held with direct (D) ownership. The filing notes the underlying shares vested on November 3, 2025.